Timing of Antidiabetic Medication Initiation and Risk of Cardiovascular Events and Mortality

Is there a difference in the risk of major adverse cardiovascular events (MACE) and mortality among individuals who initiated antidiabetic medication (ADM) within 3, 6, or 12 months after meeting the diagnostic threshold for type 2 diabetes?In this cohort study involving 23 452 participants, earlier ADM initiation after meeting the diagnostic threshold for type 2 diabetes was not associated with risk of MACE but was associated with a lower risk of mortality over a 5-year follow-up.These findings suggest health care authorities should adopt evidence-based strategies that promote timely intervention to optimize outcomes in type 2 diabetes management.

Corresponding Authors: Yoosoo Chang, MD, PhD, Center for Cohort Studies, Total Healthcare Center, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul 03181, Republic of Korea (yoosoo@skku.edu); Ju Hwan Kim, PharmD, PhD, Research Professor, School of Pharmacy, Sungkyunkwan University, 2066 Seobu-ro, Jangan-gu, Suwon-si, Gyeonggi-do 16419, South Korea (jukim928@skku.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.